Loading…
Plus Therapeutics, Inc. is projected to rise to $4.25 by 2027, a +8% move from its current price of $3.95. PSTV is currently trading below its 50-day average (a bearish sign). Technical indicators currently lean strong sell.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 7/11/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Jul 13 | $3.80 | $3.95 | $4.10 | -0.05% |
| Jul 14 | $3.74 | $3.95 | $4.16 | -0.10% |
| Jul 15 | $3.70 | $3.94 | $4.21 | -0.15% |
| Jul 16 | $3.66 | $3.94 | $4.25 | -0.20% |
| Jul 17 | $3.63 | $3.94 | $4.28 | -0.25% |
| Jul 18 | $3.59 | $3.94 | $4.31 | -0.30% |
| Jul 19 | $3.57 | $3.94 | $4.34 | -0.35% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $3.57 | $3.94 | $4.34 | -0.35% |
| Week 2 | $3.41 | $3.92 | $4.51 | -0.69% |
| Week 3 | $3.30 | $3.91 | $4.64 | -1.03% |
| Week 4 | $3.20 | $3.90 | $4.74 | -1.38% |
| Week 5 | $3.11 | $3.88 | $4.84 | -1.72% |
| Week 6 | $3.04 | $3.87 | $4.93 | -2.06% |
| Week 7 | $2.97 | $3.86 | $5.00 | -2.40% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
Plus Therapeutics, Inc. (PSTV) is a clinical-stage pharmaceutical company focused on the development, manufacture, and commercialization of treatments for patients with cancer. Its lead radiotherapeutic candidate is rhenium obisbemeda, a patented radiotherapy for patients with central nervous system and other cancers, including recurrent glioblastoma, leptomeningeal metastases, and pediatric brain cancers.
The company also develops Rhenium-188 NanoLiposome Biodegradable Alginate Microsphere to treat various solid organ cancers, such as primary and secondary liver cancers by intra-arterial injection. In addition, it develops and commercializes laboratory-developed tests comprising the CNSide Test to identify tumor cells that have metastasized to the central nervous system in patients with carcinomas and melanomas. The company was formerly known as Cytori Therapeutics, Inc.
and changed its name to Plus Therapeutics, Inc. in July 2019. Plus Therapeutics was founded in 1996 and is headquartered in Houston, Texas.
Plus Therapeutics, Inc. trades as PSTV and has a current price of $3.82 with a market cap of $26.3M. Its market ranking is 4803. This snapshot places PSTV among smaller-cap healthcare equities with a focus on oncology therapies.
The forecast landscape shows the average price moving around the current level in the near term, with potential rises to higher levels later in the horizon. In 2026 the avg price is $3.82 with a min of $2.92 and a max of $5.05, and the sentiment is NEUTRAL. From 2033 onward, the forecast enters a bullish footing, with 2033 avg $5.02 and max $8.43 and 2034 avg $5.10; 2035 avg $4.98, continuing to 2040 avg $6.79 and 2050 avg $9.22, signaling meaningful upside over the longer term.
A major floor 45.8% below — a decisive break under it would weaken the trend.
The nearest floor, 3.3% below — buyers have tended to step in here.
The nearest ceiling, 62.8% above — a clean break opens room to run.
A major ceiling 96.2% above — clearing it would confirm fresh momentum.
Key PSTV support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of PSTV market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $3.96 | Sell | $3.99 | Sell |
| MA 10 | $4.08 | Sell | $4.08 | Sell |
| MA 20 | $4.27 | Sell | $4.35 | Sell |
| MA 50 | $5.27 | Sell | $5.04 | Sell |
| MA 100 | $5.75 | Sell | $6.17 | Sell |
| MA 200 | $9.40 | Sell | $8.89 | Sell |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 36.88 | Neutral |
| Stoch RSI (14) | 85.07 | Sell |
| CCI (20) | -62.00 | Neutral |
| Williams %R (14) | -67.27 | Info |
| MACD (12,26,9) | 0.03 | Buy |
| ROC (12) | -1.96 | Sell |
| Bollinger %B (20,2) | 0.33 | Neutral |
| Stochastic %K (14) | 32.73 | Neutral |
| TRIX (15) | -1.24 | Sell |
| Awesome (5,34) | -1.00 | Sell |
| Ultimate (7,14,28) | 33.35 | Neutral |
| Momentum (10) | -0.26 | Sell |
| Aroon Osc (25) | -88.00 | Sell |
| Hull MA (9) | 3.87 | Buy |
| ADX (14) | 27.18 | Sell |
| ATR (14) | 0.16 | Info |
The 30-day technical picture is NEUTRAL with an RSI14 of 30. The 50-day simple moving average is $5.35 and the 200-day simple moving average is $9.47, indicating near-term resistance ahead of the longer-term trend.
The stock sits at a support level of $3.82 and faces resistance at $6.64. The 30-day price range runs from $2.99 to $4.89, highlighting a relatively tight trading band around the current price and a potential for movement toward the nearby resistance if demand strengthens.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $2.92 | $3.95 | $5.22 | 0% | Neutral | |
| $3.27 | $4.25 | $5.91 | +8% | Neutral | |
| $3.08 | $4.17 | $6.08 | +6% | Neutral | |
| $2.55 | $3.57 | $5.41 | -10% | Neutral | |
| $2.66 | $3.82 | $5.97 | -3% | Neutral | |
| $2.71 | $4.01 | $6.43 | +2% | Neutral | |
| $2.86 | $4.34 | $7.13 | +10% | Neutral | |
| $3.32 | $5.17 | $8.68 | +31% | Bullish | |
| $3.31 | $5.27 | $9.03 | +33% | Bullish | |
| $3.18 | $5.17 | $9.02 | +31% | Bullish | |
| $3.89 | $7.03 | $13.23 | +78% | Bullish | |
| $4.38 | $9.55 | $20.04 | +142% | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| July 2026 | $2.92 | $3.95 | $4.83 | +0.00% |
| August 2026 | $3.27 | $3.90 | $4.80 | -1.31% |
| September 2026 | $3.14 | $3.78 | $4.72 | -3.14% |
| October 2026 | $3.24 | $3.93 | $4.97 | +4.01% |
| November 2026 | $3.34 | $4.09 | $5.22 | +4.05% |
| December 2026 | $3.29 | $4.04 | $5.22 | -1.02% |
Click any year to see its month-by-month PSTV forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
The PSTV price prediction for 2026 points to an average of $3.95 (low $2.92, high $5.22) — a potential gain of 0% on today's $3.95. Price action looks broadly range-bound.
In 2027, PSTV is projected to trade between $3.27 and $5.91, averaging $4.25 — a potential gain of +8% from today's $3.95. That is up +8% on the projected 2026 average. A consolidation phase looks the most probable path here.
Plus Therapeutics, Inc.'s 2028 outlook centres on $4.17, within a $3.08 to $6.08 range. That is -2% versus the projected 2027 average. That marks a +6% change versus current levels. Price action looks broadly range-bound.
By 2029, PSTV could reach as high as $5.41, with a base case around $3.57 and support toward $2.55 — roughly -10% from $3.95. A consolidation phase looks the most probable path here.
Expect PSTV to range from $2.66 to $5.97 through 2030. The $3.82 average target implies a -3% move from current prices. That is up +7% on the projected 2029 average. Price action looks broadly range-bound.
The PSTV price prediction for 2031 points to an average of $4.01 (low $2.71, high $6.43) — a potential gain of +2% on today's $3.95. A consolidation phase looks the most probable path here.
In 2032, PSTV is projected to trade between $2.86 and $7.13, averaging $4.34 — a potential gain of +10% from today's $3.95. That is up +8% on the projected 2031 average. Price action looks broadly range-bound.
Plus Therapeutics, Inc.'s 2033 outlook centres on $5.17, within a $3.32 to $8.68 range. That is up +19% on the projected 2032 average. That marks a +31% change versus current levels. Buyers look set to stay in control over this stretch.
By 2034, PSTV could reach as high as $9.03, with a base case around $5.27 and support toward $3.31 — roughly +33% from $3.95. Momentum favours further upside here.
Expect PSTV to range from $3.18 to $9.02 through 2035. The $5.17 average target implies a +31% move from current prices. That is -2% versus the projected 2034 average. Buyers look set to stay in control over this stretch.
The PSTV price prediction for 2040 points to an average of $7.03 (low $3.89, high $13.23) — a potential gain of +78% on today's $3.95. Momentum favours further upside here.
In 2050, PSTV is projected to trade between $4.38 and $20.04, averaging $9.55 — a potential gain of +142% from today's $3.95. That is up +36% on the projected 2040 average. Buyers look set to stay in control over this stretch.
Investing $1,000 in PSTV today (≈ 253.164557 PSTV) could be worth
$2,416.91
+$1,416.91 (+142%) by 2050 · US Dollar
Based on the average projected PSTV price of $9.55 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in PSTVwould be worth at today's price.
$1,000 invested in PSTV on Jul 10, 2025 (≈ 114.285714 PSTV) would be worth
$451.43
-$548.57 (-54.9%) today · 0.45× · US Dollar
Based on a PSTV entry price of $8.75 vs. today's $3.95.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $3.98 | $992.46 | -0.8% |
| 1 month ago | $5.39 | $732.84 | -26.7% |
| 3 months ago | $4.8 | $822.92 | -17.7% |
| 6 months ago | $12.25 | $322.45 | -67.8% |
| 1 year ago | $8.75 | $451.43 | -54.9% |
| All time (5.0y) ago | $843.75 | $4.68 | -99.5% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our PSTV forecast.
Our base-case forecast reaches $7.90 around 2050.
Implied market cap at $7.90: $54.38M
The multi-year forecast shows a path from a flat-to-moderate level in the near term to stronger upside in the later years. The 2029 forecast yields an avg price of $3.44 with a -9.8% ROI and a NEUTRAL sentiment, followed by 2030 with an avg of $3.71 and a -2.9% ROI. The forecast turns more positive from 2033 onward, with 2033 avg $5.02 and ROI 31.3%, 2034 avg $5.10 and ROI 33.6%, and 2035 avg $4.98 and ROI 30.4% with BULLISH sentiment.
Further out, 2040 shows an avg of $6.79 with a 77.8% ROI, and 2050 projects an avg of $9.22 with a 141.5% ROI, continuing the bullish trend. These figures illustrate upside potential across the horizon, though earlier years also reflect periods of subdued or negative returns. It remains important to recognize these are estimates and not guarantees.
Tap a question to reveal the answer.
The 2030 forecast shows an avg price of $3.71 with a max of $5.80 and a min of $2.57, and a ROI of -2.9%.
Forecasts show NEUTRAL sentiment in 2026–2032 with positive momentum beginning in 2033 (avg $5.02, max $8.43; ROI 31.3%), followed by further upside through 2040 (avg $6.79, ROI 77.8%) and 2050 (avg $9.22, ROI 141.5%). These are estimates, not guarantees.
Yes. The 2033 forecast lists an avg of $5.02 and a max of $8.43, indicating the potential to surpass $5 as part of the longer-term upside.
Current price is $3.82. The 30-day range is $2.99 to $4.89.
RSI14 is 30 (NEUTRAL); SMA50 is $5.35 and SMA200 is $9.47, with support at $3.82 and resistance at $6.64.
Plus Therapeutics, Inc. Community Discussion
0Share your Plus Therapeutics, Inc. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.